A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.9070-9073 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9073 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 9070 |
| container_title | Blood |
| container_volume | 140 |
| creator | Zeidner, Joshua F. Foster, Matthew C. Johnson, Mary Huang, Ying Swords, Ronan T. Stein, Eytan Foran, James M. Baer, Maria R. Stock, Wendy Madanat, Yazan F. Kovacsovics, Tibor Olin, Rebecca L. Blum, William G. Schiller, Gary J. Lin, Tara L. Redner, Robert L. Al-Mansour, Zeina Curran, Emily K Heerema, Nyla A. Martycz, Molly Rosenberg, Leonard Marcus, Sonja Yocum, Ashley O. Chen, Timothy Stefanos, Mona Druggan, Franchesca Burd, Amy Levine, Ross L. Druker, Brian J. Borate, Uma Byrd, John C. Mims, Alice S. |
| description | |
| doi_str_mv | 10.1182/blood-2022-166715 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_166715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122056440</els_id><sourcerecordid>S0006497122056440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1855-e521a01c43006cfc9a4d2aad8235a489c94a93c64c8261ab6a5ae4d8a1a2acf3</originalsourceid><addsrcrecordid>eNp9kc1u00AUhS0EEqHwAOzuspE6dGb8U1usrCaFCjtE1JSfjXUzc9MOuJ7IM2lr3oAH4cV4AJ6BScOa1dFZfPcc3RNFLwV_JUQuj1edtZpJLiUTWXYi0kfRRKQyZ5xL_jiacM4zlhQn4mn0zLlvnIsklukk-lPC8hodgVjBzAadO4UdemN7wF7D_H6Dvdu5C7_VI9g1XCxmn1maifgIyh-ojDfa9ASH5ddy-sBcUk_eqg7v4fByvpiC6WFBd90IM4NXfUjRR7AMGdR7B79__oKMwxfCwcGd8dfwsfcDoScNi2UtWL31O3MMZ1UTs0-m09CMG4KyrsAO8K5uZMk-BHzA_ipApdp6gnqkzhoNFW2_043B0K-ups-jJ2vsHL34pwdRczZvTt-y6v2b89OyYkrkacoolQK5UEkc3qbWqsBES0SdyzjFJC9UkWARqyxRucwErjJMkRKdo0CJah0fRGJ_Vg3WuYHW7WYwNziMreDtbq_2Ya92t1e73yswr_cMhV63hobWqfAhRdoMpHyrrfkP_RcmypyC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Zeidner, Joshua F. ; Foster, Matthew C. ; Johnson, Mary ; Huang, Ying ; Swords, Ronan T. ; Stein, Eytan ; Foran, James M. ; Baer, Maria R. ; Stock, Wendy ; Madanat, Yazan F. ; Kovacsovics, Tibor ; Olin, Rebecca L. ; Blum, William G. ; Schiller, Gary J. ; Lin, Tara L. ; Redner, Robert L. ; Al-Mansour, Zeina ; Curran, Emily K ; Heerema, Nyla A. ; Martycz, Molly ; Rosenberg, Leonard ; Marcus, Sonja ; Yocum, Ashley O. ; Chen, Timothy ; Stefanos, Mona ; Druggan, Franchesca ; Burd, Amy ; Levine, Ross L. ; Druker, Brian J. ; Borate, Uma ; Byrd, John C. ; Mims, Alice S.</creator><creatorcontrib>Zeidner, Joshua F. ; Foster, Matthew C. ; Johnson, Mary ; Huang, Ying ; Swords, Ronan T. ; Stein, Eytan ; Foran, James M. ; Baer, Maria R. ; Stock, Wendy ; Madanat, Yazan F. ; Kovacsovics, Tibor ; Olin, Rebecca L. ; Blum, William G. ; Schiller, Gary J. ; Lin, Tara L. ; Redner, Robert L. ; Al-Mansour, Zeina ; Curran, Emily K ; Heerema, Nyla A. ; Martycz, Molly ; Rosenberg, Leonard ; Marcus, Sonja ; Yocum, Ashley O. ; Chen, Timothy ; Stefanos, Mona ; Druggan, Franchesca ; Burd, Amy ; Levine, Ross L. ; Druker, Brian J. ; Borate, Uma ; Byrd, John C. ; Mims, Alice S.</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-166715</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.9070-9073</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1855-e521a01c43006cfc9a4d2aad8235a489c94a93c64c8261ab6a5ae4d8a1a2acf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Zeidner, Joshua F.</creatorcontrib><creatorcontrib>Foster, Matthew C.</creatorcontrib><creatorcontrib>Johnson, Mary</creatorcontrib><creatorcontrib>Huang, Ying</creatorcontrib><creatorcontrib>Swords, Ronan T.</creatorcontrib><creatorcontrib>Stein, Eytan</creatorcontrib><creatorcontrib>Foran, James M.</creatorcontrib><creatorcontrib>Baer, Maria R.</creatorcontrib><creatorcontrib>Stock, Wendy</creatorcontrib><creatorcontrib>Madanat, Yazan F.</creatorcontrib><creatorcontrib>Kovacsovics, Tibor</creatorcontrib><creatorcontrib>Olin, Rebecca L.</creatorcontrib><creatorcontrib>Blum, William G.</creatorcontrib><creatorcontrib>Schiller, Gary J.</creatorcontrib><creatorcontrib>Lin, Tara L.</creatorcontrib><creatorcontrib>Redner, Robert L.</creatorcontrib><creatorcontrib>Al-Mansour, Zeina</creatorcontrib><creatorcontrib>Curran, Emily K</creatorcontrib><creatorcontrib>Heerema, Nyla A.</creatorcontrib><creatorcontrib>Martycz, Molly</creatorcontrib><creatorcontrib>Rosenberg, Leonard</creatorcontrib><creatorcontrib>Marcus, Sonja</creatorcontrib><creatorcontrib>Yocum, Ashley O.</creatorcontrib><creatorcontrib>Chen, Timothy</creatorcontrib><creatorcontrib>Stefanos, Mona</creatorcontrib><creatorcontrib>Druggan, Franchesca</creatorcontrib><creatorcontrib>Burd, Amy</creatorcontrib><creatorcontrib>Levine, Ross L.</creatorcontrib><creatorcontrib>Druker, Brian J.</creatorcontrib><creatorcontrib>Borate, Uma</creatorcontrib><creatorcontrib>Byrd, John C.</creatorcontrib><creatorcontrib>Mims, Alice S.</creatorcontrib><title>A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u00AUhS0EEqHwAOzuspE6dGb8U1usrCaFCjtE1JSfjXUzc9MOuJ7IM2lr3oAH4cV4AJ6BScOa1dFZfPcc3RNFLwV_JUQuj1edtZpJLiUTWXYi0kfRRKQyZ5xL_jiacM4zlhQn4mn0zLlvnIsklukk-lPC8hodgVjBzAadO4UdemN7wF7D_H6Dvdu5C7_VI9g1XCxmn1maifgIyh-ojDfa9ASH5ddy-sBcUk_eqg7v4fByvpiC6WFBd90IM4NXfUjRR7AMGdR7B79__oKMwxfCwcGd8dfwsfcDoScNi2UtWL31O3MMZ1UTs0-m09CMG4KyrsAO8K5uZMk-BHzA_ipApdp6gnqkzhoNFW2_043B0K-ups-jJ2vsHL34pwdRczZvTt-y6v2b89OyYkrkacoolQK5UEkc3qbWqsBES0SdyzjFJC9UkWARqyxRucwErjJMkRKdo0CJah0fRGJ_Vg3WuYHW7WYwNziMreDtbq_2Ya92t1e73yswr_cMhV63hobWqfAhRdoMpHyrrfkP_RcmypyC</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Zeidner, Joshua F.</creator><creator>Foster, Matthew C.</creator><creator>Johnson, Mary</creator><creator>Huang, Ying</creator><creator>Swords, Ronan T.</creator><creator>Stein, Eytan</creator><creator>Foran, James M.</creator><creator>Baer, Maria R.</creator><creator>Stock, Wendy</creator><creator>Madanat, Yazan F.</creator><creator>Kovacsovics, Tibor</creator><creator>Olin, Rebecca L.</creator><creator>Blum, William G.</creator><creator>Schiller, Gary J.</creator><creator>Lin, Tara L.</creator><creator>Redner, Robert L.</creator><creator>Al-Mansour, Zeina</creator><creator>Curran, Emily K</creator><creator>Heerema, Nyla A.</creator><creator>Martycz, Molly</creator><creator>Rosenberg, Leonard</creator><creator>Marcus, Sonja</creator><creator>Yocum, Ashley O.</creator><creator>Chen, Timothy</creator><creator>Stefanos, Mona</creator><creator>Druggan, Franchesca</creator><creator>Burd, Amy</creator><creator>Levine, Ross L.</creator><creator>Druker, Brian J.</creator><creator>Borate, Uma</creator><creator>Byrd, John C.</creator><creator>Mims, Alice S.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)</title><author>Zeidner, Joshua F. ; Foster, Matthew C. ; Johnson, Mary ; Huang, Ying ; Swords, Ronan T. ; Stein, Eytan ; Foran, James M. ; Baer, Maria R. ; Stock, Wendy ; Madanat, Yazan F. ; Kovacsovics, Tibor ; Olin, Rebecca L. ; Blum, William G. ; Schiller, Gary J. ; Lin, Tara L. ; Redner, Robert L. ; Al-Mansour, Zeina ; Curran, Emily K ; Heerema, Nyla A. ; Martycz, Molly ; Rosenberg, Leonard ; Marcus, Sonja ; Yocum, Ashley O. ; Chen, Timothy ; Stefanos, Mona ; Druggan, Franchesca ; Burd, Amy ; Levine, Ross L. ; Druker, Brian J. ; Borate, Uma ; Byrd, John C. ; Mims, Alice S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1855-e521a01c43006cfc9a4d2aad8235a489c94a93c64c8261ab6a5ae4d8a1a2acf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zeidner, Joshua F.</creatorcontrib><creatorcontrib>Foster, Matthew C.</creatorcontrib><creatorcontrib>Johnson, Mary</creatorcontrib><creatorcontrib>Huang, Ying</creatorcontrib><creatorcontrib>Swords, Ronan T.</creatorcontrib><creatorcontrib>Stein, Eytan</creatorcontrib><creatorcontrib>Foran, James M.</creatorcontrib><creatorcontrib>Baer, Maria R.</creatorcontrib><creatorcontrib>Stock, Wendy</creatorcontrib><creatorcontrib>Madanat, Yazan F.</creatorcontrib><creatorcontrib>Kovacsovics, Tibor</creatorcontrib><creatorcontrib>Olin, Rebecca L.</creatorcontrib><creatorcontrib>Blum, William G.</creatorcontrib><creatorcontrib>Schiller, Gary J.</creatorcontrib><creatorcontrib>Lin, Tara L.</creatorcontrib><creatorcontrib>Redner, Robert L.</creatorcontrib><creatorcontrib>Al-Mansour, Zeina</creatorcontrib><creatorcontrib>Curran, Emily K</creatorcontrib><creatorcontrib>Heerema, Nyla A.</creatorcontrib><creatorcontrib>Martycz, Molly</creatorcontrib><creatorcontrib>Rosenberg, Leonard</creatorcontrib><creatorcontrib>Marcus, Sonja</creatorcontrib><creatorcontrib>Yocum, Ashley O.</creatorcontrib><creatorcontrib>Chen, Timothy</creatorcontrib><creatorcontrib>Stefanos, Mona</creatorcontrib><creatorcontrib>Druggan, Franchesca</creatorcontrib><creatorcontrib>Burd, Amy</creatorcontrib><creatorcontrib>Levine, Ross L.</creatorcontrib><creatorcontrib>Druker, Brian J.</creatorcontrib><creatorcontrib>Borate, Uma</creatorcontrib><creatorcontrib>Byrd, John C.</creatorcontrib><creatorcontrib>Mims, Alice S.</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zeidner, Joshua F.</au><au>Foster, Matthew C.</au><au>Johnson, Mary</au><au>Huang, Ying</au><au>Swords, Ronan T.</au><au>Stein, Eytan</au><au>Foran, James M.</au><au>Baer, Maria R.</au><au>Stock, Wendy</au><au>Madanat, Yazan F.</au><au>Kovacsovics, Tibor</au><au>Olin, Rebecca L.</au><au>Blum, William G.</au><au>Schiller, Gary J.</au><au>Lin, Tara L.</au><au>Redner, Robert L.</au><au>Al-Mansour, Zeina</au><au>Curran, Emily K</au><au>Heerema, Nyla A.</au><au>Martycz, Molly</au><au>Rosenberg, Leonard</au><au>Marcus, Sonja</au><au>Yocum, Ashley O.</au><au>Chen, Timothy</au><au>Stefanos, Mona</au><au>Druggan, Franchesca</au><au>Burd, Amy</au><au>Levine, Ross L.</au><au>Druker, Brian J.</au><au>Borate, Uma</au><au>Byrd, John C.</au><au>Mims, Alice S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>9070</spage><epage>9073</epage><pages>9070-9073</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-166715</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.9070-9073 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_166715 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A32%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%201b%20Dose%20Escalation%20and%20Expansion%20Study%20of%20SNDX-5613,%20Azacitidine%20(AZA)%20and%20Venetoclax%20(VEN)%20in%20Newly%20Diagnosed,%20Patients%20%E2%89%A5%2060%20Years%20with%20Untreated%20NPM1-Mutated/%20FLT3-Wild%20Type%20AML%20or%20KMT2A-Rearranged%20Acute%20Myeloid%20Leukemia%20(AML)&rft.jtitle=Blood&rft.au=Zeidner,%20Joshua%20F.&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=9070&rft.epage=9073&rft.pages=9070-9073&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-166715&rft_dat=%3Celsevier_cross%3ES0006497122056440%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122056440&rfr_iscdi=true |